Randomized trial · people

ARA-290 eased neuropathic symptoms in sarcoidosis nerve fiber loss

Checked against the paper Randomized trialPublished by PepVault

The takeaway

This is a controlled human trial in which ARA-290 improved nerve symptoms and corneal nerve fiber density in sarcoidosis over 28 days.

Kind
Randomized trial
Studied in
People
Published
2013
Journal
Mol Med

What they tested

The team tested whether daily ARA-290 could ease symptoms in people with sarcoidosis who have small nerve fiber loss and damage (SNFLD).

How the study was done

A blinded, randomized, placebo-controlled trial in patients with sarcoidosis and documented SNFLD. They got either ARA-290 or a placebo (a dummy shot) as a daily injection under the skin for 28 days.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking ARA-290? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Patients on ARA-290 had a significant improvement in neuropathic (nerve-related) symptoms they reported themselves, compared with placebo. ARA-290 was also linked to a significant rise in the density of small nerve fibers in the cornea, the clear front layer of the eye. Patients also showed changes in how their skin sensed temperature. They walked farther on the 6-minute walk test, a measure of exercise capacity.

What it doesn’t show

Treatment lasted only 28 days, so the trial doesn't show whether the changes last or hold up over a longer course. It studied only sarcoidosis-related nerve fiber loss. The authors' view that ARA-290 could change the course of the disease is a suggestion, not something this trial tested.

The paper

Dahan et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013.

The compound

More studies on ARA-290

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking ARA-290? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo